Articles related to MEN'S HEALTH

Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.

Recent advancements in AI are driving personalized treatment approaches for localized prostate cancer. This study highlights an AI-based model that could guide the application of ADT with radiotherapy, refining treatment strategies and improving patient outcomes.

Findings from this trial may reshape how physicians perceive and prescribe testosterone-replacement therapy for middle-aged and older men with hypogonadism, with no substantial rise in major adverse cardiac events reported.

Explore how the age-old remedy of apple cider vinegar might offer modern benefits for men’s health, including weight management, blood sugar control, and cholesterol reduction.

Addressing the Underrecognized Issue of Male Osteoporosis: Evidence-based Strategies for Improved Detection and Management As the elderly population increases, osteoporosis in men, a condition often underdiagnosed and overlooked, is gaining significant prominence in public health. This self-learning activity enables healthcare professionals to gain critical insight into this issue and empower them with the latest evidence-based preventive and therapeutic strategies.

Explore the role of androgen deprivation therapy in prostate cancer treatment and its impact on patient survival and oncologic benefits. The recent NRG Oncology/Radiation Therapy Oncology Group study offers fresh insights on androgen deprivation therapy in prostate cancer treatment. The researchers focused on patients with intermediate-risk prostate cancer. They used a sample of 1,492 patients, randomly assigned to receive either escalated radiation therapy alone, or combined with short-term androgen deprivation therapy (ADT). Strikingly, the results didn’t point to a significant survival advantage. The five-year survival estimates were almost identical for both groups, at 90% and 91% respectively. Yet, when it comes to oncologic benefits, adding short-term ADT had a substantial impact. Importantly, this therapy reduced the risk for PSA relapse, distant metastasis, and prostate cancer-specific mortality by 48%, 75%, and 90% respectively. Also, patients on ADT exhibited a 38% lower risk of requiring salvage ADT. However, physicians need to be aware of the potential drawbacks. The study observed that the adverse event rates were notably higher with ADT use, at 69% compared to 21% for radiation therapy alone. Indeed, 12% of the ADT group experienced acute grade 3 or higher adverse events, compared to just 2% of the radiation-only group. […]